IL17A and atherosclerosis: IL-17A/IL-17A receptor blockade has also been shown to ameliorate the symptoms of other disorders such as atherosclerosis (Erbel et al., 2009), inflammation-sensitised encephalopathy (Ye et al., 2019) and anklyosing spondylitis (Collison, 2018).